Orzaks Ilac ve Kimya Sanayi Ticaret A.S.
BBIST:ORZAX60.00
TRY
-1.35
(-2.20%)
ISIN
TREORZK00018
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TRY
•
in mil. unless spec.Working Capital
TRY
•
in mil. unless spec.Growth Rates
TRY
•
in mil. unless spec.Quarterly Revenue
TRY
•
in mil. unless spec.Quarterly Earnings Per Share
TRY
•
in mil. unless spec.Quarterly Dividends Per Share
TRY
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Istanbul Turkey
- IPO Date
- Jul 7, 2026
- Website
- orzax.com.tr
- Similar Companies
- Business
- Orzaks Ilac ve Kimya Sanayi Ticaret A.S. is a Turkey-based pharmaceutical and consumer healthcare company engaged in the research, development, manufacturing, marketing, and distribution of dietary supplements, over-the-counter healthcare formulations, and nutritional wellness products. Founded in 2004 and headquartered in Istanbul, Turkey, the company operates as a principal operating entity within the Alyors Group. Orzaks Ilac provides an extensive portfolio of more than 300 health and nutritional products, which are systematically categorized into: premium omega-3 fatty acid and pure fish oil supplements marketed under the Ocean brand; single-vitamin and multivitamin complexes, including vitamin D3, vitamin C, and B-complex formulas; essential mineral supplements, including magnesium malate, magnesium bisglycinate, zinc, and iron complexes marketed under the Ocean and Efervit brands; advanced collagen peptides, hyaluronic acid, and beauty-from-within wellness products under the Day2Day brand; immune defense formulations, beta-glucan compounds, and herbal extracts under the Imunol brand; joint mobility, cartilage, and bone health formulas under the Cosakondrin brand; probiotic, prebiotic, and digestive health supplements under the Bigflor brand; and specialized botanical oils, effervescent nutritional tablets, pediatric supplements, and dermocosmetics. The company manufactures its product lines across various dosage delivery forms, including softgel capsules, hard capsules, standard and effervescent tablets, chewable gummies, liquid syrups, oral drops, sprays, and powder sachets, in accordance with Good Manufacturing Practice, ISO, and FDA standards. It serves domestic healthcare channels, including pharmacies and medical professionals, while exporting to more than 50 countries across Europe, the Middle East, North America, and Central Asia. In recent major developments, Orzaks Ilac completed its initial public offering on Borsa Istanbul in July 2026 under the ticker ORZAX, listing on the BIST Stars Market with a total offering size of approximately 3.62 billion Turkish Liras. To accelerate international market penetration, the company established an operational subsidiary in Uzbekistan and commenced negotiations to acquire a regional manufacturing facility. In addition, the company authorized a capital share buyback program in September 2026 to optimize its capital structure and market valuation, while continuing to invest in manufacturing capacity expansion and pharmaceutical research and development at its Istanbul facilities.